Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | DRD4 | P21917 | 7/20 | 0.37 |
| ▸ | HTR1A | P08908 | 6/20 | 0.37 |
| ▸ | DRD1 | P21728 | 6/20 | 0.37 |
| ▸ | DRD5 | P21918 | 6/20 | 0.37 |
| ▸ | DRD3 | P35462 | 6/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8753812 | 1.00 | GRM2 (0.41) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL11163414 | 0.99 | GRM2 (0.43) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL11163411 | 0.99 | GRM2 (0.43) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL11156621 | 0.96 | KDM1A (0.39) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL11156616 | 0.96 | KDM1A (0.39) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL729421 | 0.96 | GRM2 (0.43) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL872117 | 0.96 | GRM2 (0.43) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL2853509 | 0.94 | GRM2 (0.45) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL27871568 | 0.92 | KDM1A (0.41) | GRM2KDM1ARCOR1DRD2DRD4 | |
| SCHEMBL8754430 | 0.90 | CYP2C9 (0.43) | GRM2KDM1ARCOR1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470199-B2 | Five-ring liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | HTR3D, KIF23, CCND3 | GRM2 2539/4885KDM1A 821/4885RCOR1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.